Pediatric neuromuscular disorders are a group of medical conditions that affect the nervous system and/or muscles of children. These conditions can lead to varying degrees of limitations in movement, sensation, and/or autonomic function. Examples of these medical conditions include cerebral palsy, muscular dystrophy, spinal muscular atrophy, and spinal cord injury. Cerebral palsy is a condition that results from damage to the brain and can cause changes in sensation, movement, learning, and behavior. It is a type of motor disorder, which means it affects the ability to control body movements and posture. Symptoms can range from mild to severe and can include problems with muscle tone, equilibrium, coordination, and posture, as well as impaired movement. Muscular dystrophy is a group of genetic disorders that cause muscle weakness and muscle wasting. This can lead to difficulty with tasks such as walking and breathing. The most common form of muscular dystrophy is Duchenne muscular dystrophy, which affects mostly boys. Spinal muscular atrophy is a genetic condition that affects the strength and control of voluntary muscles. This can lead to muscle weakness and difficulty with movement and coordination, as well as problems with breathing. It can also cause problems with reflexes, sensation, and impaired vision. Spinal cord injury is damage to the spinal cord that causes changes in sensation, movement, and autonomic function. This can lead to paralysis and an inability to move and feel certain parts of the body. Pediatric neuromuscular disorders require a team of neurospecialists to diagnose and treat the condition, which may include physical therapy, medications, and surgery. Depending on the severity of the disorder, some children may need ongoing therapy and rehabilitation to help regain their abilities.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States